Inari Revenue, Valuation, Funding & Investors

Shiji Biotechnology is a Beijing-headquartered developer of genetic technologies for swine breeding. The company engineers pig breeds resistant to diseases like African swine fever using CRISPR gene editing. Shiji offers breeding stock, semen, and consulting services to large-scale farms across China. Established in 2016, it collaborates with the Chinese Academy of Agricultural Sciences on porcine genomics research.

Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.

Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.

Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

Formation Bio is a South San Francisco-based biotechnology firm accelerating drug development through optimized clinical trials. It partners with pharma companies like Eli Lilly to redesign trial operations, leveraging technology for faster patient recruitment and data management in oncology and rare diseases.

Colossal Biosciences is a genetic engineering firm headquartered in Austin, Texas. Founded in 2021, it develops CRISPR-based technologies to de-extinct species including the woolly mammoth by 2028, dodo bird, and Tasmanian thylacine. The company also engineers traits into endangered animals like the Asian elephant to bolster populations against climate threats. Colossal maintains research labs across the United States and collaborates with institutions such as Harvard Medical School's George Church Lab. Its work spans genomic sequencing, stem cell reprogramming, and artificial womb development to restore ecosystems worldwide.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Bodycote PLC provides thermal processing services including heat treatment, metal joining, surface coating technologies, and hot isostatic pressing. The aerospace, defence, and energy segment offer thermal processing services across applications including general aviation, aircraft, helicopters, power generation, and others. The automotive and general industrial markets segment provides thermal processing services across the automotive industry and general industries. The company has a geographical presence in the USA, France, Germany, the UK, Sweden, Netherlands. It majority of its revenue from Automotive & General Industrial segment.

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Orano Med is a Maisons-Alfort-headquartered developer of targeted alpha therapies for prostate and other cancers using bismuth-213 and lead-212 isotopes. Part of the Orano nuclear group, the company produces chelating agents and ensures isotope supply chains from facilities in France and Belgium for clinical-stage treatments.

Teijin Ltd is a Japanese industrial conglomerate engaged in healthcare, materials, textiles, and other businesses. The company organizes itself into four primary segments. The Healthcare segment manufactures and sells pharmaceuticals, medical devices, and home medical services. The Material segment covers aramid fibers, polycarbonate resins, carbon fibers, and composite molding materials. The Textiles/Products segment produces polyester fibers and textile products. The Others segment includes businesses outside the reporting segments, such as battery components, membranes, regenerative medicine, and implantable medical devices.

Ube Corp manufactures and sells chemicals, construction materials, and machinery products. The firm organizes itself into five segments based on product type. The chemicals segment, which generates more revenue than any other segment, sells a variety of chemicals including resins, rubber, silicon, and plastics. The cement and construction segment sells cement, plaster, and foundation materials to the construction and building industries. The pharmaceutical segment sells anti-allergic, anti-hypertensive, and anti-platelet drugs. The machinery and metal products segment sells die-casting and electric injection machines. The energy and environment segment generates electricity from coal and biomass. The majority of revenue comes from Japan.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.